The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

NCI names 11 winners of its Cancer Clinical Investigator Team Leadership Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NCI recognized 11 investigators nationwide with its Cancer Clinical Investigator Team Leadership Awards.

The awards support clinical investigators at NCI-designated cancer centers who participate in NCI-funded clinical trials. Established in 2009, the awards are intended to help retain investigators in academic clinical research careers. The award provides partial salary support for 2 years for the recipient to engage in activities and efforts related to the award.

The 2015 recipients are:

  • Leora Horn, of Vanderbilt-Ingram Cancer Center
  • David Hyman, of Memorial Sloan-Kettering Cancer Center
  • Matthew Katz, of MD Anderson Cancer Center
  • Edward Kim, of UC Davis Comprehensive Cancer Center
  • Frederick Lansigan, of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
  • Charles Leath III, of University of Alabama at Birmingham Comprehensive Cancer Center
  • Elizabeth Plimack, of Fox Chase Cancer Center
  • Andrew Poklepovic, of Massey Cancer Center at Virginia Commonwealth University
  • Yvonne Saenger, of Columbia University’s Herbert Irving Comprehensive Cancer Center
  • Emma Scott, of Oregon Health & Science University Knight Cancer Institute
  • Liza Villaruz, of the University of Pittsburgh Cancer Institute

For details of the 2016 program announcement, open through Dec. 4, visit the NCI website.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account